Latest news

Thumbnail image for Government unveils plans to accelerate access to medicine

Government unveils plans to accelerate access to medicine

The government has finally published its long-awaited response to the Accelerated Access Review, with plans for a new Accelerated Access Pathway that will open a new channel providing patients with faster access to the most innovative medicines and technologies.

3rd November 2017

Thumbnail image for Novartis, Amgen, BAI start new Alzheimer’s prevention study

Novartis, Amgen, BAI start new Alzheimer’s prevention study

Novartis, Amgen and the Banner Alzheimer's Institute (BAI) have expanded their collaboration to initiate a new study investigating BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer's disease symptoms in a high-risk population.

3rd November 2017

Thumbnail image for UK children experiencing chronic delays in ADHD diagnosis

UK children experiencing chronic delays in ADHD diagnosis

Young people in the UK with ADHD are at “serious risk of social and mental health harm” because they experience some of the “longest and most complicated” delays to diagnosis anywhere in Europe, a group of experts is warning.

3rd November 2017

Thumbnail image for Final NICE nod for Sanofi’s Kevzara

Final NICE nod for Sanofi’s Kevzara

The National Institute for Health and Care Excellence has issued final guidance backing Sanofi’s Kevzara as a new treatment option for adults with severe, active rheumatoid arthritis (RA).

2nd November 2017

Thumbnail image for EU OKs low-dose Xarelto to prevent recurrent VTE

EU OKs low-dose Xarelto to prevent recurrent VTE

A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients.

2nd November 2017

Thumbnail image for NICE back Roche’s Tecentriq for CDF

NICE back Roche’s Tecentriq for CDF

The National Institute for Health and Care Excellence is recommending Roche’s Tecentriq for use within the Cancer Drugs Fund to treat advanced urothelial cancer in certain circumstances.

1st November 2017

Thumbnail image for AZ, Incyte to test lung cancer combo in PhIII

AZ, Incyte to test lung cancer combo in PhIII

AstraZeneca and MedImmune have expanded their clinical collaboration with Incyte to carry out a late-stage trial assessing an experimental combination therapy for lung cancer.

1st November 2017

Previous  --   12 13 14 15 16 17 18 19 20 21   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download